我是 LongbridgeAI，我可以總結文章信息。Portage Biotech Inc. (PRTG) 週一股價上漲超過 27%，創下三週以來的最佳表現，此次上漲是由於其間皮瘤試驗的新臨牀前數據的發佈。數據顯示，PORT-7，一種選擇性腺苷 A2B 受體抑制劑，在小鼠間皮瘤模型中顯示出有效性，導致散户投資者的樂觀情緒增加
Portage Biotech Inc.'s (PRTG) shares soared over 27% on Monday, marking their best session in more than three weeks, after the company announced new preclinical data from its mesothelioma trial. The fresh evidence confirmed the efficacy of PORT-7, Portage's selective adenosine A2B receptor inhibitor, in a murine mesothelioma model. The company said...